Precision oncology: Charting a path forward to broader deployment of genomic profiling

English version České info

In this Perspective, David Hyman and coauthors discuss clinical research on the application of genomic information in oncology.

Vyšlo v časopise: Precision oncology: Charting a path forward to broader deployment of genomic profiling. PLoS Med 14(2): e32767. doi:10.1371/journal.pmed.1002242
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002242

Souhrn

In this Perspective, David Hyman and coauthors discuss clinical research on the application of genomic information in oncology.

Zdroje

1. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45. doi: 10.1038/nbt1486 18846087

2. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023–31. doi: 10.1038/nbt.2696 24142049

3. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn. 2015;17:251–64. doi: 10.1016/j.jmoldx.2014.12.006 25801821

4. Schrader KA, Cheng DT, Joseph V, Prasad M, Walsh M, Zehir A, et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol. 2016;2:104–11. doi: 10.1001/jamaoncol.2015.5208 26556299

5. Niu B, Ye K, Zhang Q, Lu C, Xie M, McLellan MD, et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinforma Oxf Engl. 2014;30:1015–16.

6. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014;60:1192–99. doi: 10.1373/clinchem.2014.223677 24987110

7. de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature. 2010;467:543–49. doi: 10.1038/nature09339 20882008

8. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015;33:2753–62. doi: 10.1200/JCO.2014.60.4165 26014291

9. Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, et al. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. J Oncol Pract Am Soc Clin Oncol. 2016;12:e396–404.

10. NCI-MATCH / EAY131 Interim Analysis. In: ECOG-ACRIN [cited 17 Sep 2016]. http://ecog-acrin.org/nci-match-eay131/interim-analysis

11. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1:e000023. doi: 10.1136/esmoopen-2015-000023 27843590

12. Hong DS, Farago AF, Brose MS, Burris HA, Dowlati A, Bauer TM, et al. Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16–20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr CT008.

13. Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:1683–96. doi: 10.1016/S1470-2045(16)30392-8 27836716

14. Siu LL, Lawler M, Haussler D, Knoppers BM, Lewin J, Vis DJ, et al. Facilitating a culture of responsible and effective sharing of cancer genome data. Nat Med. 2016;22:464–71. doi: 10.1038/nm.4089 27149219

15. Peguero JA, Knost JA, Bauer TM, Taylor MH, Braiteh FS, Eder JP, et al. Successful implementation of a novel trial model: The Signature program [abstract]. J Clin Oncol. 2015;33 (suppl; abstr 106)